ライフサイエンスコーパス: venlafaxine

1 ranging from 4.9% for primidone to 93.8% for venlafaxine .

2 nged from 0.72 (norfluoxetine) to 1310 ng/L (venlafaxine).

3 ndomized controlled trials of fluoxetine and venlafaxine.

4 e and 2461 adults receiving extended-release venlafaxine.

5 roduced larger effects than extended-release venlafaxine.

6 toms and produces fewer adverse effects than venlafaxine.

7 ne, fluvoxamine, paroxetine, reboxetine, and venlafaxine.

8 d 8 weeks of treatment with extended-release venlafaxine.

9 tcome 8 weeks later following treatment with venlafaxine.

10 ine, paroxetine, reboxetine, sertraline, and venlafaxine.

11 icating that acupuncture was as effective as venlafaxine.

12 more likely not to tolerate extended-release venlafaxine.

13 ercent and 25.0 percent for extended-release venlafaxine.

14 re effectively reduces hot flashes than does venlafaxine.

15 aline, and 28.2 percent for extended-release venlafaxine.

16 nt and after 2 and 8 weeks of treatment with venlafaxine.

17 of venlafaxine but not from the high dose of venlafaxine.

18 y of the new extended-release formulation of venlafaxine.

19 rolol, O-desmethylvenlafaxine, tramadol, and venlafaxine.

20 done, fluoxetine, bupropion, paroxetine, and venlafaxine.

21 duced stress model of disease and reduced by venlafaxine.

22 gnificant increase in suicidal ideation with venlafaxine.

23 ially involved in the mechanism of action of venlafaxine.

24 ssion in depressed older adults treated with venlafaxine.

25 serotonin norepinephrine reuptake inhibitor venlafaxine.

26 o significantly reduced after treatment with venlafaxine.

27 lateral ultrabrief pulse ECT, augmented with venlafaxine.

28 , nortriptyline, paroxetine, sertraline, and venlafaxine.

29 scitalopram, sertraline, or extended-release venlafaxine.

30 orhynchus mykiss) were exposed to waterborne venlafaxine (0.2 and 1.0 mug/L) for 7 days.

31 oxetine initiators compared to initiators of venlafaxine (0.7/1000 person-years [PY] [95 % CI: 0.2 -

32 e cycloalkanol ethylamine scaffold, of which venlafaxine ( 1) is a member, was undertaken to develop

33 rine reuptake inhibitors (duloxetine, 0.71%; venlafaxine, 1.54%), a tricyclic antidepressant (amitrip

34 revealed that combining normetanephrine with venlafaxine (10 mg/kg, i.p.), at a dose of normetanephri

35 .1]; and posttreatment: IPT, 16.2 [7.1], and venlafaxine, 10.9 [8.6]).

36 4 weeks, during which time patients received venlafaxine 12.5 mg orally twice daily.

37 eatment with medication (fluoxetine 20 mg or venlafaxine 150 mg) or placebo.

38 enlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxine 150 mg).

39 cognitive behavioral therapy; (3) switch to venlafaxine (150-225 mg); or (4) switch to venlafaxine p

40 Venlafaxine (16 treatment groups) had an initially incre

41 uid to maternal serum ratios were higher for venlafaxine: 172% (SD=91%) (N=3).

42 assigned to sertraline plus placebo (17%) or venlafaxine (19%), but the differences did not reach sig

43 r tranylcypromine was 36.9 mg (SD=18.5); for venlafaxine, 210.3 mg (SD=95.2); and for mirtazapine, 35

44 scores at pretreatment: IPT, 22.7 [2.7], and venlafaxine, 22.4 [3.1]; and posttreatment: IPT, 16.2 [7

45 al daily dose of 200 mg, or extended-release venlafaxine (250 patients) at a maximal daily dose of 37

46 Participants were assigned placebo (n=56) or venlafaxine 37.5 mg daily (n=56), 75 mg daily (n=55), or

47 mg intramuscularly for a single dose versus venlafaxine 37.5 mg per day for a week, then 75 mg per d

48 a for the whole study period (50 placebo, 49 venlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxin

49 nstipation) were significantly higher in the venlafaxine 75 mg and 150 mg groups than in the placebo

50 riod (50 placebo, 49 venlafaxine 37.5 mg, 43 venlafaxine 75 mg, 49 venlafaxine 150 mg).

51 ized to receive escitalopram, sertraline, or venlafaxine (8 weeks) and healthy control subjects (n =

52 of the clinically effective antidepressant, venlafaxine (a serotonin (5-HT) and NE reuptake inhibito

53 y investigated rCBF and clinical response to venlafaxine, a novel antidepressant.

54 The antidepressant venlafaxine, a selective serotonin and norepinephrine re

55 Venlafaxine, a serotonin-norepinephrine reuptake inhibit

56 selective serotonin reuptake inhibitor, and venlafaxine, a serotonin-norepinephrine reuptake inhibit

57 Venlafaxine, a widely prescribed antidepressant, is a se

58 Embryonic exposure to venlafaxine accelerated early development, increased hat

59 Also, venlafaxine, acesulfame, bezafibrate, irbesartan, valsar

60 Platelet 5-HT uptake was inhibited by venlafaxine across the dose range and by sertraline but

61 Chronic venlafaxine administration (14 days, 10 mg/kg, s.c.) eli

62 rtioxetine (aHR=0.78, 95% CI: 0.63-0.96) and venlafaxine (aHR=0.92, 95% CI: 0.86-0.98).

63 scitalopram, sertraline, or extended-release venlafaxine (all substrates for P-glycoprotein) in a lar

64 Venlafaxine also increased the transcript levels of gene

65 hormonal medications (such as paroxetine and venlafaxine) also can be effective.

66 for 2421 adults receiving immediate-release venlafaxine and 2461 adults receiving extended-release v

67 e was no difference in response rate between venlafaxine and a second SSRI (48.2%; 95% CI, 41%-56% vs

68 four antidepressants (bupropion, sertraline, venlafaxine and citalopram) and olanzapine demonstrated

69 ve disorder conducted by the manufacturer of venlafaxine and desvenlafaxine completed by March 2011.

70 es were observed on these parameters between venlafaxine and either sertraline plus placebo or sertra

71 weeks: milk protein powder and placebo pill, venlafaxine and milk protein powder, soy protein powder

72 combination treatment with extended-release venlafaxine and mirtazapine in patients with treatment-r

73 Both venlafaxine and mirtazapine showed optimal acceptability

74 of dietary restrictions, and ease of use of venlafaxine and mirtazapine suggest that this combinatio

75 preventive treatments include amitriptyline, venlafaxine and mirtazapine, as well as some selected no

76 at inhibiting both uptake 1 and uptake 2 via venlafaxine and normetanephrine, respectively, elicits a

77 The relationship of venlafaxine and of benzodiazepines to self-harm events r

78 ignificant difference was identified between venlafaxine and placebo groups in the number of episodes

79 lure among duloxetine initiators compared to venlafaxine and possibly SSRIs, but not untreated patien

80 SSRI was just as efficacious as a switch to venlafaxine and resulted in fewer adverse effects.

81 fferences did not reach significance between venlafaxine and sertraline plus placebo or sertraline pl

82 der, soy protein powder and placebo pill, or venlafaxine and soy protein powder.

83 The IQs of the venlafaxine and SSRI groups were significantly lower tha

84 could explain the delayed onset of action of venlafaxine and the rapid onset of action but lack of lo

85 (N=37) were enrolled into a 12-week trial of venlafaxine and underwent five functional magnetic reson

86 hedrine and pseudoephedrine), antidepressant venlafaxine, and beta-blocker atenolol.

87 essants (citalopram, paroxetine, sertraline, venlafaxine, and bupropion, and their metabolites norflu

88 Patients given imipramine, venlafaxine, and duloxetine had more discontinuations du

89 e serotonin reuptake inhibitors, nefazodone, venlafaxine, and mirtazapine) in participants younger th

90 lysis model with flexible splines for SSRIs, venlafaxine, and mirtazapine.

91 Mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more effi

92 ebo, desvenlafaxine, paroxetine, sertraline, venlafaxine, and vortioxetine had lower all-cause discon

93 In conclusion, desvenlafaxine, paroxetine, venlafaxine, and vortioxetine had reasonable efficacy, a

94 oxetine, reboxetine, sertraline, tianeptine, venlafaxine, and vortioxetine outperformed placebo.

95 e, escitalopram, gabapentin, paroxetine, and venlafaxine are available and are associated with a redu

96 The antidepressants fluoxetine and venlafaxine are efficacious for major depressive disorde

97 hot flash scores were reduced by 55% in the venlafaxine arm versus 79% in the MPA arm (P < .0001).

98 ndomized trials of bupropion, sertraline, or venlafaxine as an adjunct to a mood stabilizer.

99 (MPA), depot preparation, versus daily oral venlafaxine as treatment for hot flashes.

100 pressant venlafaxine metabolite, O-desmethyl venlafaxine, as top priority.

101 trabrief pulse ECT, combined with open-label venlafaxine at seven academic medical centers.

102 Collectively, our results demonstrate that venlafaxine, at environmentally realistic levels, is a n

103 e, but not the delayed-onset antidepressant, venlafaxine, attenuated the previously acquired FG7142-i

104 d several of the newer antidepressants, with venlafaxine being the best studied to date.

105 ressant medications and four classes tested, venlafaxine (beta = -0.12, p = 0.002) and bupropion (bet

106 Lithium, venlafaxine, bupropion, quetiapine, olanzapine, ziprasid

107 rotiline from sertraline and the low dose of venlafaxine but not from the high dose of venlafaxine.

108 Venlafaxine but not ketamine induced a positive bias whe

109 s associated with response to sertraline and venlafaxine, but not escitalopram.

110 uggested that newer antidepressants, such as venlafaxine, can diminish hot flashes.

111 typical (fluoxetine, citalopram, reboxetine, venlafaxine, clomipramine) and atypical antidepressants

112 ditional treatment effect for sertraline and venlafaxine compared with fluoxetine.

113 Compared with mice that receive concurrent venlafaxine, corticosterone-treated mice also display re

114 low dose of a relatively new antidepressant, venlafaxine, could abrogate this clinical problem.

115 We previously showed that zygotic venlafaxine deposition alters larval behavior in zebrafi

116 We tested the hypothesis that venlafaxine deposition in the egg, mimicking maternal tr

117 was observed for citalopram, fluoxetine, and venlafaxine despite almost complete attenuation (80 to 1

118 Here we tested the hypothesis that venlafaxine disrupts central serotonergic development, l

119 Overall, zygotic exposure to venlafaxine disrupts early development, including brain

120 Group 2 received venlafaxine during phase 1 of the trial and placebo in p

121 children born to 1) depressed women who took venlafaxine during pregnancy (N=62), 2) depressed women

122 Venlafaxine (Effexor), the therapy of choice for these s

123 For venlafaxine, enhancement of connectivity between the orb

124 ale total scores at end point were -51.7 for venlafaxine ER and -43.9 for placebo (P = .006).

125 Remission rates were 50.9% for venlafaxine ER and 37.5% for placebo (P = .01).

126 nse rates were significantly greater for the venlafaxine ER and paroxetine groups (58.6% and 62.5%, r

127 The venlafaxine ER group also showed significantly greater i

128 mprovement was significantly greater for the venlafaxine ER group than for the placebo group in clust

129 Venlafaxine ER is effective in the short-term treatment

130 Venlafaxine ER treatment was significantly superior to p

131 The mean maximum daily dose of venlafaxine ER was 221.5 mg/d.

132 In this study, venlafaxine ER was effective and well tolerated in short

133 However, the subordinate fish from the venlafaxine-exposed group had significantly higher plasm

134 The venlafaxine-exposed larvae were less active and covered

135 reuptake inhibitor (SSRI)-exposed women; (3) venlafaxine-exposed women; and (4) women exposed to dulo

136 Venlafaxine exposure decreased the offspring number of F

137 We provide evidence that venlafaxine exposure reduces serotonin immunoreactivity

138 repinephrine reuptake inhibitors (SNRIs, eg, venlafaxine extended release) remain first-line pharmaco

139 SSRIs such as sertraline, and SNRIs such as venlafaxine extended release.

140 ot achieve remission during a pre-trial with venlafaxine extended-release (150-300 mg/day) were rando

141 treatment with escitalopram, sertraline, or venlafaxine extended-release and assessed at baseline an

142 pressant drugs (escitalopram, sertraline, or venlafaxine extended-release).

143 nin-specific reuptake inhibitors [SSRI]), or venlafaxine-extended release (serotonin and norepinephri

144 serotonin-norepinephrine reuptake inhibitor, venlafaxine-extended release (XR).

145 n randomized to escitalopram, sertraline, or venlafaxine-extended release, and were assessed using th

146 treatment ADMs: escitalopram, sertraline or venlafaxine-extended release.

147 ts) of the newer antidepressants paroxetine, venlafaxine, fluoxetine, and sertraline decreased hot fl

148 Although treatment with venlafaxine for MDD symptoms has been shown to reduce de

149 lectroconvulsive therapy (ECT) combined with venlafaxine for the treatment of geriatric depression.

150 duloxetine for those not eligible to receive venlafaxine) for treatment-resistant depression.

151 The venlafaxine group experienced 18 incidences of adverse e

152 By 2 weeks post-treatment, the venlafaxine group experienced significant increases in h

153 In a pooled analysis, the extended-release venlafaxine group showed a significantly greater mean de

154 with statistical parametric mapping 96, the venlafaxine group showed right posterior temporal and ri

155 The extended-release venlafaxine group showed statistically significant impro

156 levels were observed in the extended-release venlafaxine group.

157 sits, earlier year of study, and study drug (venlafaxine>desvenlafaxine).

158 equate separation of isomeric metabolites of venlafaxine, haloperidol, or adatanserin.

159 We hypothesized that venlafaxine hydrochloride and interpersonal psychotherap

160 or longer were randomly assigned to receive venlafaxine hydrochloride ER (75-225 mg/d), paroxetine (

161 n daily doses were 201.7 mg (SD, 38.1 mg) of venlafaxine hydrochloride ER and 46.0 mg (SD, 7.9 mg) of

162 Evidence indicates that venlafaxine hydrochloride extended release (ER) effectiv

163 Venlafaxine hydrochloride extended release (with doses o

164 se major depression had failed to remit with venlafaxine hydrochloride monotherapy, 91 received aripi

165 45 years received either 75 mg or 375 mg of venlafaxine hydrochloride per day, the 5-HT uptake inhib

166 ct evidence suggests that the antidepressant venlafaxine hydrochloride selectively inhibits serotonin

167 Extended-release venlafaxine hydrochloride was started at 37.5 mg/d and i

168 e, mirtazapine, bupropion hydrochloride, and venlafaxine hydrochloride) are associated with lower sui

169 ine hydrochloride, paroxetine hydrochloride, venlafaxine hydrochloride, and sertraline hydrochloride.

170 Fifteen patients took 37.5 mg twice-daily of venlafaxine hydrochloride.

171 amine maleate, paroxetine hydrochloride, and venlafaxine hydrochloride; however, these differences we

172 is was tested by microinjecting embryos with venlafaxine immediately after fertilization and performi

173 pose the midbrain region as a key target for venlafaxine impact and the mode of action involves abnor

174 Soy protein, but not venlafaxine, improved measures of QoL.

175 otion regulation, it remains unclear whether venlafaxine improves specific attentional functions.

176 However, co-injection of serotonin alongside venlafaxine in embryos recovered brain serotonin immunor

177 ne, doxepin, haloperidol, nortriptyline, and venlafaxine in human plasma samples using magnetic restr

178 serotonin/norepinephrine reuptake inhibitor venlafaxine in male mice.

179 to predict the likelihood of remission with venlafaxine in older adults with major depression.

180 ed doses of once-daily extended-release (XR) venlafaxine in outpatients with generalized anxiety diso

181 tive control before and after treatment with venlafaxine in patients with MDD compared to untreated h

182 ived placebo during phase 1 of the trial and venlafaxine in phase 2 of the trial.

183 safety, and tolerability of extended-release venlafaxine in the treatment of pediatric generalized an

184 , randomised trial to assess the efficacy of venlafaxine in women with a history of breast cancer or

185 Chronic venlafaxine increases MMP-9 levels in murine cortex, and

186 uloxetine initiators, 21,000 were matched to venlafaxine initiators, 28,479 to SSRI initiators, and 2

187 g., mirtazapine: IRR=1.55, 95% CI=1.50-1.61; venlafaxine: IRR=1.22, 95% CI=1.12-1.32), switching (ami

188 (amitriptyline: IRR=1.45, 95% CI=1.15-1.81; venlafaxine: IRR=1.47, 95% CI=1.20-1.80), augmentation,

189 Venlafaxine is an effective non-hormonal treatment for h

190 Venlafaxine is the first antidepressant in a new drug cl

191 ilateral ultrabrief pulse ECT, combined with venlafaxine, is a rapidly acting and highly effective tr

192 Extended-release venlafaxine may be an effective, well-tolerated short-te

193 Sertraline, unlike venlafaxine, may turn out to be a true environmental thr

194 egabalin (MD -2.79, 95% CrI -3.69 to -1.91), venlafaxine (MD -2.69, 95% CrI -3.50 to -1.89), and esci

195 groups improved substantially, more so with venlafaxine (mean [SD] HAM-D scores at pretreatment: IPT

196 ylase-positive cell populations, and rescued venlafaxine-mediated behavioral changes.

197 abolite galaxolidone, and the antidepressant venlafaxine metabolite, O-desmethyl venlafaxine, as top

198 uracy 59.7%, p=0.023), but not in a combined venlafaxine-mirtazapine group (n=140; accuracy 51.4%, p=

199 ceived a flexible dosage of extended-release venlafaxine (N=157) or placebo (N=163) for 8 weeks.

200 39), sertraline (N=238), or extended-release venlafaxine (N=250) or to continue taking citalopram and

201 studies in which either fluoxetine (N=24) or venlafaxine (N=27) was the active medication.

202 elease bupropion [N=28], or extended-release venlafaxine [N=31]).

203 aracteristics have been recently introduced: venlafaxine, nefazodone, mirtazapine, and reboxetine.

204 Neither venlafaxine nor soy protein alone or in combination had

205 In androgen-deprived men, neither venlafaxine nor soy proved effective in reducing hot fla

206 Several compounds (citalopram, venlafaxine, O-desmethyl-venlafaxine) were not attenuate

207 , methamphetamine, sertraline, tramadol, and venlafaxine) on European perch (Perca fluviatilis) durin

208 iting uptake 2 alone, or in conjunction with venlafaxine, on extracellular levels of NE and 5-HT.

209 ained-release bupropion, or extended-release venlafaxine or an augmentation with sustained-release bu

210 which survivors of breast cancer were given venlafaxine or placebo for control of hot flashes.

211 ase who initiated duloxetine to comparators (venlafaxine or selective serotonin reuptake inhibitors [

212 inhibition of 87% or more in subjects taking venlafaxine or sertraline.

213 a medication switch alone (alternate SSRI or venlafaxine) or a medication switch plus cognitive-behav

214 am, fluoxetine, paroxetine, and sertraline), venlafaxine, or mirtazapine in the acute treatment of ad

215 clonazepam), a switch to up to 225 mg/day of venlafaxine, or prolonged sertraline treatment with plac

216 ned to sertraline plus clonazepam, switch to venlafaxine, or sertraline plus placebo.

217 mechanisms of action sequentially engaged by venlafaxine over its clinically relevant dose range.

218 In an intention-to-treat analysis, 46% of venlafaxine patients (50 of 109) compared with 74% of th

219 r the first time that early life exposure to venlafaxine perturbs brain development, which may be due

220 We tested the hypothesis that venlafaxine perturbs brain monoamine levels and disrupts

221 ne, 5.4 (4.4) episodes (Delta8.4) during the venlafaxine phase, and 5.0 (4.6) episodes (Delta8.8) dur

222 o venlafaxine (150-225 mg); or (4) switch to venlafaxine plus cognitive behavioral therapy.

223 andomly assigned to receive pharmacotherapy (venlafaxine plus lithium) or pharmacotherapy plus contin

224 nal ECT [STABLE] algorithm, while continuing venlafaxine plus lithium).

225 mized treatment arms: a medication only arm (venlafaxine plus lithium, over 24 weeks) and an ECT plus

226 r tranylcypromine (N=58) or extended-release venlafaxine plus mirtazapine (N=51).

227 the tranylcypromine group and 13.7% for the venlafaxine plus mirtazapine group).

228 anylcypromine group and the extended-release venlafaxine plus mirtazapine group, and the rates were n

229 Immediate-release venlafaxine produced larger effects than extended-releas

230 quetiapine (aHR=0.79, 95% CI: 0.67-0.93) and venlafaxine-quetiapine (aHR=0.82, 95% CI: 0.73-0.91) vs.

231 We have previously shown that venlafaxine reduces PNN deposition and increases the pow

232 enes, which were tested for association with venlafaxine remission (a MADRS score </=10) and changes

233 regions compared with nonresponders, whereas venlafaxine responders had lower functional connectivity

234 Venlafaxine resulted in a weaker degree of improvement a

235 hese results demonstrate that treatment with venlafaxine selectively normalizes the executive control

236 compared the effects of prenatal exposure to venlafaxine (serotonin-norepinephrine reuptake inhibitor

237 ta from unpublished trials of citalopram and venlafaxine show unfavourable risk-benefit profiles.

238 Tramadol and venlafaxine showed constant concentrations in the spiked

239 mazepine (SMD, -1.57 [CrI, -2.83 to -0.31]), venlafaxine (SMD, -1.53 [CrI, -2.41 to -0.65]), duloxeti

240 The children exposed to venlafaxine, SSRIs, and maternal depression during pregn

241 Patients received either 1 venlafaxine tablet, 37.5 mg, taken daily by mouth for 8

242 .60) and continuation trials (ratio=3.75) of venlafaxine than in the acute and continuation trials of

243 curring dry mouth in patients who were given venlafaxine than in those given placebo (week 1 [baselin

244 significantly greater with extended-release venlafaxine than placebo (69% versus 48%).

245 frequent occurrence of skin problems during venlafaxine than SSRI treatment.

246 executive control, and after treatment with venlafaxine, the performance of the MDD group on executi

247 55% from baseline during the fourth week of venlafaxine therapy.

248 ketamine to the medial prefrontal cortex and venlafaxine to the amygdala.

249 with the study drug, seven (78%) of the nine venlafaxine-treated subjects and two (22%) of the nine p

250 esults suggest that clinicians discontinuing venlafaxine treatment should consider tapering the medic

251 All venlafaxine treatment started at 37.5 mg daily and gradu

252 ile there were no main effects of treatment, venlafaxine treatment was associated with a higher rate

253 nts (bupropion, mirtazapine, nefazodone, and venlafaxine), tricyclic antidepressants, or no antidepre

254 eived protocolized treatment with open-label venlafaxine, up to 300 mg/day for approximately 12 weeks

255 Overall, mirtazapine and venlafaxine users had the most adverse outcomes compared

256 citalopram, sertraline, and extended-release venlafaxine), using multivariable linear and logistic re

257 oxetine, reboxetine, sertraline, tianeptine, venlafaxine, vilazodone, and vortioxetine) and a placebo

258 , citalopram (CLP; 5.45 mug/capita/day), and venlafaxine (VLF; 3.59 mug/capita/day).

259 Compared to placebo, venlafaxine was associated with a lower incidence of diz

260 three antidepressants included in the study, venlafaxine was associated with the highest relative ris

261 tinuation of treatment with extended-release venlafaxine was compared with the rate associated with d

262 single randomized studies, extended-release venlafaxine was more efficacious than paroxetine, lithiu

263 A trial of venlafaxine was performed with seven patients referred w

264 Venlafaxine was started during the first week of treatme

265 Venlafaxine was the predominant antidepressant observed

266 Paroxetine, duloxetine, desvenlafaxine, and venlafaxine were associated with increases in total chol

267 pounds (citalopram, venlafaxine, O-desmethyl-venlafaxine) were not attenuated.

268 y-carbamazepine, O-desmethylvenlafaxine, and venlafaxine, were found to be stable in the HZ.

269 ent ranged from 3 (duloxetine) to 2190 ng/L (venlafaxine), whereas individual concentrations in the w

270 e) were microinjected with either 1 or 10 ng venlafaxine, which led to a rapid reduction (90%) of thi

271 onstants of atorvastatin, carbamazepine, and venlafaxine, which react primarily with (3)DOM and (1)O(

272 limbic blood flow increase with IPT yet not venlafaxine, while both treatments demonstrated increase

273 omized to a switch to either another SSRI or venlafaxine, with or without cognitive behavior therapy.

274 er selective serotonin reuptake inhibitor or venlafaxine, with or without cognitive-behavioral therap

275 onded better and had fewer side effects with venlafaxine, with the better response most apparent for

276 bo (32.4%) were lower than after 6 months on venlafaxine XR (53.7%) (P < .03).

277 were randomly assigned to receive placebo or venlafaxine XR (75, 150, or 225 mg/day) for 8 weeks.

278 ation versus switching to the antidepressant venlafaxine XR (or duloxetine for those not eligible to

279 Open-label venlafaxine XR (titrated up to 300 mg/d) for 12 weeks.

280 rates in phase 2 (months 6-12) were 9.8% on venlafaxine XR and 53.7% on placebo (P < .001).

281 evealed a significant difference between the venlafaxine XR and placebo groups in improvement on the

282 to safeguard against assigning patients with venlafaxine XR discontinuation symptoms or temporary anx

283 ommon new or worsening adverse effect in the venlafaxine XR group compared with the placebo group ove

284 e significantly lower for one or more of the venlafaxine XR groups in four of four primary and three

285 Venlafaxine XR is an effective and well-tolerated option

286 ith venlafaxine XR, followed by double-blind venlafaxine XR or placebo for 2 relapse phases, each las

287 atment, improved patients were randomized to venlafaxine XR or placebo for 6 months.

288 tudy at 12 months were randomized to receive venlafaxine XR or placebo, and all placebo patients cont

289 All venlafaxine XR patients still in the study at 12 months

290 Participants receiving venlafaxine XR reported significantly less SCI-related d

291 After 6 months' open-label venlafaxine XR treatment, improved patients were randomi

292 Twelve-week trial of venlafaxine XR vs placebo using a flexible-dose algorith

293 Venlafaxine XR was well tolerated by most patients and a

294 All doses of venlafaxine XR were well tolerated.

295 Six months' open-label treatment with venlafaxine XR, followed by double-blind venlafaxine XR

296 to respond after 12 weeks of treatment with venlafaxine XR.

297 a differential moderator of non-response to venlafaxine-XR (Cohen's d effect size 1.5; classificatio

298 re randomized to escitalopram, sertraline or venlafaxine-XR antidepressants and assessed at follow-up

299 decrease in NAc-insula FC (p < 0.001) and to venlafaxine-XR by an increase in NAc-inferior temporal g

300 Non-responders to venlafaxine-XR showed pre-treatment hyper-reactivity, wh

301 ost-ADM treatment (randomized to sertraline, venlafaxine-XR, or escitalopram).